Linked e-resources
Details
Table of Contents
Foreword; Foreword; Foreword; Foreword; Preface; The Evolution ofßAdolescent Oncology inßtheßUnited States; Background; A Decade ofßExperience: 1978-1989; Scaling Up: 1992-The Present; References; Contents; 1: Adolescent andßYoung Adult Oncology: Historical andßGlobal Perspectives; References; 2: Cancer Incidence, Survival, andßMortality Among Adolescents andßYoung Adults; 2.1 Introduction; 2.2 Sources ofßInformation andßModes ofßAnalysis: Incidence, Survival, andßMortality; 2.2.1 Age; 2.3 Data Sources andßAnalyses; 2.3.1 Incidence; 2.3.2 Survival; 2.3.3 Mortality.
2.4 Global, Regional, andßNational Perspectives2.4.1 Incidence; 2.4.1.1 Cancer Incidence Worldwide; 2.4.1.2 Worldwide Geographic Variation; 2.4.1.3 Overall Incidence byßSingle Years ofßAge (US SEER); 2.4.1.4 Individual Cancer Incidence byß5-Year Age Intervals (US SEER); 2.4.1.5 Individual Cancer Incidence byßAge Group, Site, andßSex (US SEER); 2.4.1.6 Incidence Trends byßSite (US SEER); 2.4.2 Survival; 2.4.2.1 Site Distribution andßSurvival (Europe, US SEER, Japan); 2.4.2.2 Survival forßAYAs Compared toßChildren (Age <15ßYears).
2.4.2.3 Survival forßAYAs Compared toßOlder Adults (Age 40-69)2.4.2.4 Survival Trends; 2.4.3 Mortality; 2.4.3.1 Cancer Mortality Worldwide; 2.4.3.2 Death Rates andßTrends by Site; 2.5 Etiology, Biology, Trends, andßInternational Progress; Appendix; References; 3: The Biology ofßAYA Cancers; 3.1 Introduction; 3.2 Old Questions andßNew Technologies; 3.3 Four AYA Cancers withßBiologic Distinction; 3.3.1 Colorectal Cancer; 3.3.2 Acute Lymphoblastic Leukemia; 3.3.3 Breast Cancer; 3.3.4 Melanoma; 3.3.5 Sarcoma; 3.4 Summary; References; 4: Non-Hodgkin Lymphoma; 4.1 Introduction.
4.2 Epidemiology4.2.1 Age-Specific Incidence; 4.2.2 Incidence ofßHistologic Types; 4.3 Etiology/Risk Factors; 4.4 Histology/Cytogenetics; 4.5 Clinical Features; 4.6 Initial Workup andßStaging; 4.7 B-Cell Non-Hodgkin Lymphoma; 4.7.1 Burkitt Lymphoma; 4.7.2 Diffuse Large B-Cell Lymphoma; 4.7.2.1 Primary Mediastinal B-Cell Lymphoma; 4.7.3 Anaplastic Large Cell Lymphoma; 4.7.3.1 Biology/Pathology; 4.7.3.2 Management ofßS-ALCL; 4.7.3.3 Management ofßC-ALCL; 4.7.3.4 Prognostic Factors; 4.7.3.5 Treatment ofßRelapses; 4.8 Lymphoblastic Lymphoma; 4.8.1 Biology/Pathology.
4.8.2 Treatment andßManagement4.9 Rare Non-Hodgkin Lymphomas inßAdolescents andßYoung Adults; 4.10 Overall Survival; References; 5: Hodgkin Lymphoma; 5.1 Introduction; 5.2 Epidemiology; 5.2.1 Incidence; 5.2.1.1 Age andßGender; 5.2.1.2 Race andßEthnicity; 5.3 Etiology andßPathogenesis; 5.4 Pathology; 5.5 Presenting Features; 5.6 Diagnostic Testing; 5.6.1 Tissue Diagnosis; 5.6.2 Other Laboratory Studies; 5.6.3 Imaging Studies; 5.7 Staging andßRisk Assessment; 5.7.1 Risk Strata forßTreatment Determination; 5.8 Therapy; 5.8.1 General Principles.
2.4 Global, Regional, andßNational Perspectives2.4.1 Incidence; 2.4.1.1 Cancer Incidence Worldwide; 2.4.1.2 Worldwide Geographic Variation; 2.4.1.3 Overall Incidence byßSingle Years ofßAge (US SEER); 2.4.1.4 Individual Cancer Incidence byß5-Year Age Intervals (US SEER); 2.4.1.5 Individual Cancer Incidence byßAge Group, Site, andßSex (US SEER); 2.4.1.6 Incidence Trends byßSite (US SEER); 2.4.2 Survival; 2.4.2.1 Site Distribution andßSurvival (Europe, US SEER, Japan); 2.4.2.2 Survival forßAYAs Compared toßChildren (Age <15ßYears).
2.4.2.3 Survival forßAYAs Compared toßOlder Adults (Age 40-69)2.4.2.4 Survival Trends; 2.4.3 Mortality; 2.4.3.1 Cancer Mortality Worldwide; 2.4.3.2 Death Rates andßTrends by Site; 2.5 Etiology, Biology, Trends, andßInternational Progress; Appendix; References; 3: The Biology ofßAYA Cancers; 3.1 Introduction; 3.2 Old Questions andßNew Technologies; 3.3 Four AYA Cancers withßBiologic Distinction; 3.3.1 Colorectal Cancer; 3.3.2 Acute Lymphoblastic Leukemia; 3.3.3 Breast Cancer; 3.3.4 Melanoma; 3.3.5 Sarcoma; 3.4 Summary; References; 4: Non-Hodgkin Lymphoma; 4.1 Introduction.
4.2 Epidemiology4.2.1 Age-Specific Incidence; 4.2.2 Incidence ofßHistologic Types; 4.3 Etiology/Risk Factors; 4.4 Histology/Cytogenetics; 4.5 Clinical Features; 4.6 Initial Workup andßStaging; 4.7 B-Cell Non-Hodgkin Lymphoma; 4.7.1 Burkitt Lymphoma; 4.7.2 Diffuse Large B-Cell Lymphoma; 4.7.2.1 Primary Mediastinal B-Cell Lymphoma; 4.7.3 Anaplastic Large Cell Lymphoma; 4.7.3.1 Biology/Pathology; 4.7.3.2 Management ofßS-ALCL; 4.7.3.3 Management ofßC-ALCL; 4.7.3.4 Prognostic Factors; 4.7.3.5 Treatment ofßRelapses; 4.8 Lymphoblastic Lymphoma; 4.8.1 Biology/Pathology.
4.8.2 Treatment andßManagement4.9 Rare Non-Hodgkin Lymphomas inßAdolescents andßYoung Adults; 4.10 Overall Survival; References; 5: Hodgkin Lymphoma; 5.1 Introduction; 5.2 Epidemiology; 5.2.1 Incidence; 5.2.1.1 Age andßGender; 5.2.1.2 Race andßEthnicity; 5.3 Etiology andßPathogenesis; 5.4 Pathology; 5.5 Presenting Features; 5.6 Diagnostic Testing; 5.6.1 Tissue Diagnosis; 5.6.2 Other Laboratory Studies; 5.6.3 Imaging Studies; 5.7 Staging andßRisk Assessment; 5.7.1 Risk Strata forßTreatment Determination; 5.8 Therapy; 5.8.1 General Principles.